Cytological and spectroscopic characteristics of c-KIT N822K mutation in core binding factor acute myeloid leukemia cells

被引:6
|
作者
Chen, Yang [1 ]
Wang, Lingyan [2 ]
Lin, Xindi [1 ]
Zhang, Qian [1 ]
Xu, Yunchao [3 ]
Lin, Donghong [1 ]
Xu, Jianping [1 ]
Feng, Shangyuan [3 ]
Hu, Jianda [1 ,2 ]
机构
[1] Fujian Med Univ, Dept Lab Med, 88 Jiaotong RD, Fuzhou, Peoples R China
[2] Fujian Med Univ, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol,Union Hosp, Fuzhou, Peoples R China
[3] Fujian Normal Univ, Key Lab Optoelect Sci & Technol Med, Minist Educ, Fuzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
CBF-AML; chromosome translocation; c-KIT N822K mutation; flow cytometry; laser tweezers Raman spectroscopy; LOOP TYROSINE 823; RAMAN-SPECTROSCOPY; ACTIVATION LOOP; TWEEZERS; SURVIVAL;
D O I
10.1002/jbio.202000103
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
The frequency of N822K mutation is high in the A-loop region of c-KIT which is highly associated with poor prognosis of core binding factor acute myeloid leukemia. The current work used common assays including cell cycle, apoptosis, clone formation and western blot to perform cytological detection for HL60 (wild type), NB4 (carrying t[15;17] chromosome translocation) and Kasumi-1 (with c-KIT N822K mutation); and meanwhile, the laser tweezers Raman spectroscopy (LTRS) was also used to perform label-free detection of single living cells. The results demonstrated that Kasumi-1 cell line bearing c-KIT N822K mutation has a stable cell cycle, while there was a significant difference between early and late apoptosis within 48 hours. The LTRS detection initially reflected the spectral differences induced by genetic abnormalities and highlighted progressive patterns of DNA and amino acids band contents which were appropriately consistent with that of cell clone ratio and the c-KIT phosphorylation level. It is concluded that methodology of LTRS-based single living cell characterization could be potential and effective to reveal gene mutation-induced cell differentiation.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Reactivation of PP2A as a treatment strategy for c-KIT+ core-binding factor acute myeloid leukemia
    Roberts, Kathryn
    Smith, Amanda
    Carpenter, Helen
    Santhanam, Ramasamy
    Sim, Alistair
    Ashman, Leonie
    Perrotti, Danilo
    Verrills, Nicole
    CANCER RESEARCH, 2009, 69
  • [42] Dasatinib inhibits proliferation and induces apoptosis in the KASUMI-1 cell line bearing the t(8;21)(q22;q22) and the N822K c-kit mutation
    Mpakou, Vassiliki E.
    Kontsioti, Frieda
    Papageorgiou, Sotiris
    Spathis, Aris
    Kottaridi, Christine
    Girkas, Kostas
    Karakitsos, Petros
    Dimitriadis, George
    Dervenoulas, Ioannis
    Pappa, Vasiliki
    LEUKEMIA RESEARCH, 2013, 37 (02) : 175 - 182
  • [43] Systemic mastocytosis associated with acute myeloid leukemia:: Report of a new c-kit mutation Asp816His.
    Pullarkat, VA
    Pullarkat, ST
    Calverley, DC
    Brynes, RK
    BLOOD, 1999, 94 (10) : 493A - 493A
  • [44] Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia
    W Jang
    J-H Yoon
    J Park
    G D Lee
    J Kim
    A Kwon
    H Choi
    K Han
    C H Nahm
    H-J Kim
    W-S Min
    M Kim
    Y Kim
    Blood Cancer Journal, 2016, 6 : e387 - e387
  • [45] Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia
    Jang, W.
    Yoon, J-H
    Park, J.
    Lee, G. D.
    Kim, J.
    Kwon, A.
    Choi, H.
    Han, K.
    Nahm, C. H.
    Kim, H-J
    Min, W-S
    Kim, M.
    Kim, Y.
    BLOOD CANCER JOURNAL, 2016, 6 : e387 - e387
  • [46] In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation
    Beghini, A
    Cairoli, R
    Morra, E
    Larizza, L
    BLOOD CELLS MOLECULES AND DISEASES, 1998, 24 (12) : 262 - 270
  • [47] Mutation of c-KIT and Platelet-Derived Growth Factor Receptor (PDGFR) a genes in childhood acute myeloid leukemia and leukemic cell lines.
    Hiwatari, M
    Taki, T
    Tsuchida, M
    Hanada, R
    Hongo, T
    Sako, M
    Hayashi, Y
    BLOOD, 2003, 102 (11) : 865A - 865A
  • [48] Core binding factor acute myeloid leukemia: Advances in the heterogeneity of KIT, FLT3, and RAS mutations
    Quan, Xi
    Deng, Jianchuan
    MOLECULAR AND CLINICAL ONCOLOGY, 2020, 13 (02) : 95 - 100
  • [49] Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of C-KIT, FLT3, and JAK2 mutations on clinical outcome
    Markova, Jana
    Trnkova, Zuzana
    Michkova, Petra
    Maaloufova, Jacqueline
    Stary, Jan
    Cetkovsky, Petr
    Schwarz, Jiri
    LEUKEMIA & LYMPHOMA, 2009, 50 (09) : 1448 - 1460
  • [50] Both the Subtypes of Kit Mutation and Minimal Residual Disease Are Associated with Prognosis in Core Banding Factor Acute Myeloid Leukemia
    Duan, Wenbing
    Liu, Xiaohong
    Jia, Jinsong
    Wang, Jing
    Gong, Lizhong
    Jiang, Qian
    Zhao, Ting
    Wang, Yu
    Zhang, Xiaohui
    Xu, Lanping
    Zhao, Xiaosu
    Qin, Yazhen
    Shi, Hongxia
    Chang, Yingjun
    Huang, Xiaojun
    Jiang, Hao
    BLOOD, 2020, 136